Aspirin in coronary heart disease. The Coronary Drug Project Research Group

J Chronic Dis. 1976 Oct;29(10):625-42.


PIP: 1529 men with a history of myocardial infarction (MI) and previously treated with either dextrothyroxine or estrogen therapy in the Coronary Drug Project were selected for a study on the administration of aspirin on a daily basis. Patients received 324 mg aspirin daily or a placebo on a double-blind basis. Follow-up ranged from 10-28 months and was carried out at 4-month intervals. 60% of the patients were over 55 years and approximately 1/3 had had 2 MIs. There were 32 dropouts from the program. Patients taking aspirin experienced 30% fewer deaths (5.8% compared to 8.3%). For combined fatal and nonfatal events the aspirin group was 21% lower than the placebo group. The differences seen are suggestive of a beneficial effect of aspirin but the data are from too small a sample to be conclusive.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aspirin / therapeutic use*
  • Clinical Trials as Topic
  • Dextrothyroxine / therapeutic use
  • Drug Evaluation
  • Estrogens / therapeutic use
  • Humans
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Placebos


  • Estrogens
  • Placebos
  • Dextrothyroxine
  • Aspirin